Publications by authors named "Buer Li"

Claim this Profile
S
SLAMF7 promotes TCRαβ double negative T cell antitumor activity through enhancing glutamine metabolism.
Nan Xu, Peiyang Fang, Longyang Zhou, Xiaotong Han, Yuan Jiang, Buer Li

J Exp Clin Cancer Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients with AMA/anti-sp100/anti-gp210 Positivity and Cholestasis Can Manifest Conditions Beyond Primary Biliary Cholangitis.
Xin Zeng, Tingting Lv, Shuxiang Li, Sha Chen, Buer Li

J Clin Transl Hepatol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IFITM1 aggravates ConA-Induced autoimmune hepatitis by promoting NKT cell activation through increased AMPK-Dependent mitochondrial function.
Jie Sun, Haozhe Xu, Buer Li, Wanqing Deng, Xiaotong Han

Int Immunopharmacol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Add-on immunosuppressive therapy may benefit selected patients with primary biliary cholangitis and autoimmune phenomena.
Mengqi Li, Sha Chen, Shuxiang Li, Tingting Lv, Buer Li, Min Li

Therap Adv Gastroenterol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concomitant extrahepatic autoimmune diseases do not compromise the long-term outcomes of primary biliary cholangitis.
Sha Chen, Meng-Qi Li, Wei-Jia Duan, Bu-Er Li, Shu-Xiang Li, Lin Ma

Hepatobiliary Pancreat Dis Int· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The future risk of primary biliary cholangitis (PBC) is low among patients with incidental anti-mitochondrial antibodies but without baseline PBC.
Weijia Duan, Sha Chen, Shuxiang Li, Tingting Lv, Buer Li

Hepatol Commun· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis